Search Results
Feb 10, 2026, 09:05 ET Neuspera Medical Announces Milestone Case of Traditional Sacral Neuromodulation (SNM) System Removed and Replaced With the Company's Integrated SNM System for Urinary Urge Incontinence
[email protected]:Bretschneider CE, et al. "Device-Related Reoperations 8 Years Following Sacral Neuromodulation Implantation in Older Women". Int Urogynecol J. 2024 Dec;35(12):2349-2355.Axonics Modulation Technologies, Inc. Form 10-K for the fiscal year ended October 5, 2018. U.S. Securities
More news about: Neuspera Medical
Feb 03, 2026, 08:00 ET AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
2.Krüger C, Schallreuter KU. Int J Dermatol. 2012;51(10):1206–123.
More news about: AbbVie
Jan 29, 2026, 09:25 ET CW Bancorp Reports Fourth Quarter 2025 and Full Year Financial Results
Int Bearing Due from Banks & FFS$
More news about: CW Bancorp
Jan 28, 2026, 09:00 ET First Community Corporation Announces Fourth Quarter and Year End 2025 Results and Cash Dividend
3.46 % Int bearing deposits in other banks166,018
More news about: First Community Corporation
Jan 26, 2026, 16:05 ET LINKBANCORP, Inc. Announces Fourth Quarter 2025 and Full Year 2025 Financial Results and Declares Dividend
Yield/RateInt. Earn. Cash
More news about: LINKBANCORP, Inc.
Jan 26, 2026, 14:30 ET Study Shows NanoFuse® Superiority: Why Bioactive Glass-DBM Composites Outperform DBM and Bioactive Glass Alone
Osteoinductive Potential of BMP-2, Bioactive Glass, and Demineralized Bone Matrix: An In Vitro Alkaline Phosphatase Assay Study," appears in Int J Spine Surg , Volume 19, Issue 6 (December 2025). Recombinant human BMP-2 was included in the study solely as a reference control to
More news about: NanoFUSE Biologics
Jan 25, 2026, 21:48 ET Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
doi:10.1038/s41467-021-23507-z.[2] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.[3] Hampel H, Hardy J, Blennow K, et al. The
More news about: BioArctic
Jan 25, 2026, 21:45 ET Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA
doi:10.1038/s41467-021-23507-z.[2] Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.[3] Hampel H, Hardy J, Blennow K, et al. The
More news about: BioArctic
Jan 25, 2026, 18:30 ET FDA Accepts LEQEMBI® IQLIKTM (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
doi:10.1038/s41467-021-23507-z.Ono K, Tsuji M. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease. Int J Mol Sci. 2020;21(3):952. doi: 10.3390/ijms21030952. PMID: 32023927; PMCID: PMC7037706.Hampel H, Hardy J, Blennow K, et al. The amyloid-β pathway
More news about: Eisai Inc.
Jan 22, 2026, 08:10 ET Healthcare Triangle, Inc. Signs Definitive Agreement with Teyame AI LLC which is forecasted to generate $38M in incremental NTM Revenue and incremental NTM EBITDA of $5M in addition to expanding its SaaS Footprint in Europe and Latin America
is-forecasted-to-generate-38m-in-incremental-ntm-revenue-and-incremental-ntm-ebitda-of-5m-in-addition-to-expanding-its-saas-footprint-in-europe-and-la-302667586.htmlSOURCE Healthcare Triangle, Inc.
More news about: Healthcare Triangle, Inc.
Jan 21, 2026, 07:30 ET Keenova Marks 100K Peyronie's Disease Patients--a Major Milestone for an Often-Stigmatized Men's Health Condition
al. PLoS One. 2016;11(2):e0150157.DiBenedetti DB, Nguyen D, Zografoset L, et al. Adv Urol. 2011:282503.Hellstrom WJ. Int J Impot Res. 2003;15:S91-S92.Contacts:
More news about: Keenova Therapeutics
Jan 21, 2026, 05:00 ET File1099 Forms Online with ez1099 2025 No IRS TCC Needed
ez1099 20252025 Form 1099 Series - including 1099-A, 1099-B, 1099-C, 1099-CAP, 1099-DA , 1099-DIV, 1099-G, 1099-INT, 1099-K, 1099-LS, 1099-LTC, 1099-MISC, 1099-NEC, 1099-OID, 1099-PATR, 1099-Q, 1099-QA, 1099-R, 1099-S, 1099-SA, 1099-SB)2025 Form 1098
More news about: Halfpricesoft.com
Jan 21, 2026, 02:15 ET AM Group unterzeichnet wegweisende Absichtserklärung mit der Regierung von Uttar Pradesh zur Einrichtung eines GW-Scale-KI-Rechenzentrums, das die Demokratisierung der KI von Elektronenagenten bis hin zu intelligenten Tokens ermöglicht
content:https://www.prnewswire.com/news-releases/am-group-unterzeichnet-wegweisende-absichtserklarung-mit-der-regierung-von-uttar-pradesh-zur-einrichtung-eines-gw-scale-ki-rechenzentrums-das-die-demokratisierung-der-ki-von-elektronenagenten-bis-hin-zu-intelligenten-tokens-ermog-302666425.html
More news about: AM Group
Jan 20, 2026, 14:37 ET Zilliz Announces General Availability of Milvus 2.6.x on Zilliz Cloud, Powering Billion-Scale Vector Search at Even Lower Cost
Multilingual Retrieval for More AI Use Cases Milvus 2.6.x on Zilliz Cloud adds native support for spatial data, timezone-aware timestamps, INT8 vectors, and nested structures, alongside improved multilingual tokenization and phrase search—enabling complex, global AI applications
More news about: Zilliz
Jan 16, 2026, 06:49 ET Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN
here.ReferencesSmith RJH, et al. Nat Rev Nephrol. 2019;15(3):129-143.Servais A, et al. Kidney Int. 2012;82(4):454-464.Zand L, et al. J Am Soc Nephrol. 2014;25(5):1110-1117.Tarragón, B, et al. Clin J Am Soc Nephrol 2024; 19(8)1005-1015.Data
More news about: Swedish Orphan Biovitrum AB
Jan 15, 2026, 17:00 ET New ez1099 efile Service Helps Businesses Meet Critical Deadlines!
ez1099 20252025 Form 1099 Series - including 1099-A, 1099-B, 1099-C, 1099-CAP, 1099-DA , 1099-DIV, 1099-G, 1099-INT, 1099-K, 1099-LS, 1099-LTC, 1099-MISC, 1099-NEC, 1099-OID, 1099-PATR, 1099-Q, 1099-QA, 1099-R, 1099-S, 1099-SA, 1099-SB)2025 Form 1098
More news about: Halfpricesoft.com
Jan 15, 2026, 09:00 ET Playlist and EGYM Announce Agreement to Merge and $785 Million in New Equity Investments, Bringing Together Global Leaders in Fitness and Wellness Technology
egym.com/int.About Affinity PartnersAffinity Partners is a Miami-based investment firm founded in 2021 by Jared Kushner. With over $5.7B
More news about: Playlist
Jan 14, 2026, 09:00 ET Monetizing Sustainability: How Environmental Assets Are Driving Profitable Opportunities
renewable fuel platform and aligns with its recently signed non-binding Memorandum of Understanding ("MOU") with global energy and commodities group BGN INT US LLC ("BGN"). As contemplated by the MOU, subject to the negotiation of a definitive agreement, XCF and BGN intend to jointly develop global distribution,
More news about: Market News Updates
Jan 13, 2026, 07:47 ET Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
progress INT230-6 across multiple development pathways, in an attempt to build long-term shareholder value through consistent execution."About INT230-6INT230-6, Intensity's lead proprietary investigational product candidate, is designed for direct intratumoral injection. INT230-6 was
More news about: Intensity Therapeutics Inc.
Jan 06, 2026, 09:00 ET Hesai Selected by NVIDIA as Lidar Partner for NVIDIA DRIVE Hyperion 10 to Enable Level 4 Fleet Deployment
DRIVE AGX Thor systems-on-a-chip built on the NVIDIA Blackwell architecture, DRIVE Hyperion delivers more than 2,000 FP4 teraflops — or roughly 1,000 INT8 trillion operations per second — of real‑time compute to fuse a full 360‑degree sensor view."Everything that moves will eventually become autonomous,
More news about: Hesai Technology
Jan 05, 2026, 06:30 ET MulticoreWare Demonstrates Real-Time Cloud-to-Car AI Workflow with Qualcomm AI HUB and QCR100 Instance at CES 2026
Hub & MulticoreWare Workflow for OEMsSeamless Model Optimization: Smooth transition from FP32 to quantized INT8/INT16 models.Scalable Cloud Workflow: On-demand access to QCR100 instances for global validation and CI/CD pipelines without on-premises
More news about: MulticoreWare Inc.
Dec 25, 2025, 21:29 ET 青島自由貿易区：生命健康産業は「ビーズ」を連ねて「チェーン」になる
青島（中国）、2025年12月26日 /PRNewswire/ -- Chengda Int. Mediaより：世界初の免疫抗腫瘍海洋糖類新薬であるBG136が2期治験を順調に推進している。同薬は、青島国信製薬が中国海洋大学等と共同で開発し、南極褐藻を原料とし、進行性固形腫瘍の治療に用いられ、2028年に条件付きで発売される見込みである。これは青島自由貿易区の生命健康産業のステップアップの生き生きとした縮図である。青島の遺伝子と細胞産業の資源集中区として、青島自由貿易区（中徳生態園）は政策上のサポートを継続的に強化し、生命健康産業プロジェクトを62件集積し、省レベル以上の
More news about: CHENGDA(QINGDAO) INTERNATIONAL MEDIA CO.,LTD.
Dec 25, 2025, 01:39 ET 中国の青島：5年間で1兆7000億元までまい進し、発展の新たなベンチマークを鋳造
青島（中国）、2025年12月25日 /PRNewswire/ -- Chengda Int. Mediaより： 青島市が最新発表したデータによると、過去5年間で全市の地域総生産（GDP）は連続5段で千億元レベルの階段を跨い、2025年には歴史的に1兆7000億元を突破する見通しである。この飛躍は、青島の都市機能レベルの実質的な飛躍を示しているだけでなく、年平均5.9%の着実な成長率も複雑で変化に富んだ経済環境の下での青島の強大な靭性と澎湃たる活力を更に示している。●革新で駆動し、質の高い発展の「強いエ
More news about: CHENGDA(QINGDAO) INTERNATIONAL MEDIA CO.,LTD.
Dec 22, 2025, 05:00 ET ez1099 Now Offers Electronic Filing Service, Add-On Feature!
submissionsComprehensive Form Support:2025 Form 1099 Series: 1099-A, 1099-B, 1099-C, 1099-CAP, 1099-DA, 1099-DIV, 1099-G, 1099-INT, 1099-K, 1099-LS, 1099-LTC, 1099-MISC, 1099-NEC, 1099-OID, 1099-PATR, 1099-Q, 1099-QA, 1099-R, 1099-S, 1099-SA, 1099-SB,2025 Form 1098 Series:
More news about: Halfpricesoft.com
Dec 19, 2025, 09:00 ET Tolmar Announces Expanded Indication for Rubraca® (rucaparib) First and Only PARP Inhibitor to Outperform Docetaxel in a Head-to-Head Phase 3 Trial
November 2025 3 Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011;65(11):1180–11924 Olmos, D. et al. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer
More news about: TOLMAR